These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 1654294)
1. The effects of recombinant desulphatohirudin on arterial thrombosis in rats. Talbot MD; Ambler J; Butler KD; Lees CM; Mitchell KA; Peters RF; Tweed MF; Wallis RB Haemostasis; 1991; 21 Suppl 1():73-9. PubMed ID: 1654294 [TBL] [Abstract][Full Text] [Related]
2. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Agnelli G; Pascucci C; Cosmi B; Nenci GG Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121 [TBL] [Abstract][Full Text] [Related]
3. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789 [TBL] [Abstract][Full Text] [Related]
5. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044 [TBL] [Abstract][Full Text] [Related]
6. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Peters RF; Lees CM; Mitchell KA; Tweed MF; Talbot MD; Wallis RB Thromb Haemost; 1991 Mar; 65(3):268-74. PubMed ID: 1710836 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001 [TBL] [Abstract][Full Text] [Related]
8. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
9. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998 [TBL] [Abstract][Full Text] [Related]
10. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. Buchwald AB; Sandrock D; Unterberg C; Ebbecke M; Nebendahl K; Lüders S; Munz DL; Wiegand V J Am Coll Cardiol; 1993 Jan; 21(1):249-54. PubMed ID: 7678021 [TBL] [Abstract][Full Text] [Related]
11. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274 [TBL] [Abstract][Full Text] [Related]
12. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336 [TBL] [Abstract][Full Text] [Related]
13. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009 [TBL] [Abstract][Full Text] [Related]
14. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model. Doutremepuich C; Lalanne MC; Doutremepuich F; Walenga J; Fareed J; Breddin HK Haemostasis; 1991; 21 Suppl 1():99-106. PubMed ID: 1894201 [TBL] [Abstract][Full Text] [Related]
16. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons. Kotzé HF; Lamprecht S; Badenhorst PN Blood; 1995 Jun; 85(11):3158-63. PubMed ID: 7756648 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Kaiser B; Simon A; Markwardt F Thromb Haemost; 1990 Feb; 63(1):44-7. PubMed ID: 2140204 [TBL] [Abstract][Full Text] [Related]
18. Antithrombotic action of recombinant hirudin in a venous thrombosis model. Raake W; Klauser RJ; Elling H; Zeiller P Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor. Arnljots B; Bergqvist D Plast Reconstr Surg; 1995 Apr; 95(5):894-900. PubMed ID: 7708874 [TBL] [Abstract][Full Text] [Related]
20. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model. Krupinski K; Breddin HK Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]